Biopharma dealmaking remained active this week as large pharmaceutical companies continued to reinforce their oncology and biologics pipelines through strategic platform acquisitions. The most substantial transaction came from Johnson & Johnson, which announced plans to acquire Halda Therapeutics in a deal valued at approximately $3.05 billion, adding Halda’s RIPTAC™ targeted protein degradation platform and its lead prostate-cancer candidate HLD-0915 to J&J’s growing precision-oncology portfolio [1]. This signals continued industry demand for differentiated oncology mechanisms as patent cliffs approach for several major therapeutics.
Meanwhile, Eli Lilly advanced its strategy in next-generation biologics through a major licensing and collaboration agreement with ABL Bio, gaining access to the Grabody™ bispecific antibody platform and its potential in both oncology and CNS indications [2]. With an upfront payment and total deal value exceeding US $2.5 billion, this partnership reflects how large pharmas are moving quickly to secure enabling technologies rather than traditional single-asset acquisitions.
On the leadership front, ViVac Pharma Ltd. appointed Keren Leshem as Chief Executive Officer—a move that brings deep translational, regulatory, and commercial expertise to the company as it advances its programmable RNA–LNP immunotherapy pipeline [3]. Her appointment reinforces the trend of emerging biotech platforms recruiting seasoned operators to navigate scale-up and clinical inflection points.
Collectively, this week’s activity demonstrates three structural themes:
- Platform-centric M&A is accelerating, particularly in protein degradation, bispecifics, and RNA/LNP immunology.
- Cross-border innovation sourcing is increasing, with U.S.–Asia partnerships becoming more common.
- Leadership upgrades continue as biotechs position for clinical maturity, financing, and partner engagement.
📚 References
[1] Johnson & Johnson Investor Newsroom — Acquisition of Halda Therapeutics.
https://www.investor.jnj.com/investor-news/news-details/2025/Johnson–Johnson-Set-to-Revolutionize-the-Treatment-of-Cancer-With-the-Acquisition-of-Halda-Therapeutics/default.aspx
[2] BioWorld — ABL Bio’s Grabody platform lands US$2.6B deal with Eli Lilly.
https://www.bioworld.com/articles/726156-abl-bios-grabody-lands-second-26b-deal-this-time-with-lilly
[3] PR Newswire — ViVac Pharma appoints Keren Leshem as CEO.
https://www.prnewswire.com/news-releases/vivac-appoints-keren-leshem-as-chief-executive-officer-strengthening-leadership-to-advance-rna-lipid-nanoparticle-immunotherapy-platform-302621837.html
Just tell me!